Physiological role of endothelin-1 in flow-mediated vasodilatation in humans and impact of cardiovascular risk factors

Objectives: The current study addressed the hypothesis that the local decrease in endothelin-1 (ET-1) bioavailability during sustained flow increases contributes to endothelium-dependent, flow-mediated dilatation (FMD) of conduit arteries and is altered in presence of cardiovascular risk factors. Methods and results: In nine young healthy individuals, the decrease in local ET-1 plasma levels and radial artery FMD in response to hand skin heating (from 34 to 44 °C) was not affected by endothelin type A (ETA) receptor blockade, achieved using the brachial infusion of BQ-123 (100 nmol/min per l of forearm), as compared with physiological saline (0.9% NaCl) infusion. In contrast, endothelin type B (ETB) receptor blockade with BQ-788 (10 nmol/min per l) suppressed the decrease in plasma ET-1 during heating and reduced FMD, without altering nitric oxide release. The coinfusion of BQ-123 did not affect the inhibitory effect of ETB receptor blockade on the decrease in ET-1 plasma levels during heating but prevented the reduction in FMD. Basal radial artery parameters, systemic hemodynamics, and endothelium-independent dilatation to glyceryl trinitrate were not modified by ETA and/or ETB blockade. In a general population of 40 participants without treatment or major cardiovascular diseases, including the nine healthy individuals, the reduction in endothelin-1 level during heating was correlated with FMD (r = −0.55, P < 0.001) and decreased with increased age (r = 0.49, P = 0.001), mean arterial blood pressure (r = 0.48, P = 0.002), and total cholesterol level (r = 0.37, P = 0.024). Conclusion: The uptake of endothelin-1 by ETB receptors contributes to conduit artery FMD, preventing its vasoconstrictor action mediated by ETA receptors. The alteration of this mechanism by cardiovascular risk factors may contribute to endothelial dysfunction.

[1]  R. Cannon,et al.  Role of endothelin in the increased vascular tone of patients with essential hypertension. , 1999, Hypertension.

[2]  A. Quyyumi,et al.  Endogenous Endothelin in Human Coronary Vascular Function: Differential Contribution of Endothelin Receptor Types A and B , 2007, Hypertension.

[3]  D. Webb,et al.  Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. , 1999, Hypertension.

[4]  R. Cannon,et al.  Increased activity of endogenous endothelin in patients with hypercholesterolemia. , 2000, Journal of the American College of Cardiology.

[5]  D. Webb,et al.  Systemic ETA receptor antagonism with BQ‐123 blocks ET‐1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men , 2001, British journal of pharmacology.

[6]  G. Kenny,et al.  Endothelin‐1 modulates methacholine‐induced cutaneous vasodilatation but not sweating in young human skin , 2016, The Journal of physiology.

[7]  D. Webb,et al.  Contribution of endogenous generation of endothelin-1 to basal vascular tone , 1994, The Lancet.

[8]  C. DeSouza,et al.  Sex Steroids and Gender in Cardiovascular-Renal Physiology and Pathophysiology Sex differences in endothelin-1-mediated vasoconstrictor tone in middle-aged and older adults , 2010 .

[9]  W E Haefeli,et al.  Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.

[10]  C. Thuillez,et al.  Epoxyeicosatrienoic Acids Contribute With Altered Nitric Oxide and Endothelin-1 Pathways to Conduit Artery Endothelial Dysfunction in Essential Hypertension , 2012, Circulation.

[11]  D. Webb,et al.  Endogenous Endothelin-1 Limits Exercise-Induced Vasodilation in Hypertensive Humans , 2002, Hypertension.

[12]  Gian Paolo Rossi,et al.  Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. , 2005, Journal of hypertension.

[13]  T. Nagase,et al.  Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. Tardif,et al.  Reduced pulmonary clearance of endothelin-1 in pulmonary hypertension. , 1998, American heart journal.

[15]  J. Panza,et al.  Sex-Specific Effects of Cardiovascular Risk Factors on Endothelium-Dependent Dilation and Endothelin Activity in Middle-Aged Women and Men , 2015, PloS one.

[16]  C. DeSouza,et al.  Endothelin-1 Vasoconstrictor Tone Increases With Age in Healthy Men But Can Be Reduced by Regular Aerobic Exercise , 2007, Hypertension.

[17]  T. Lüscher,et al.  ETA Receptors Mediate Vasoconstriction of Large Conduit Arteries During Reduced Flow in Humans , 2003, Journal of cardiovascular pharmacology.

[18]  R. Khalil,et al.  Vascular endothelin receptor type B: structure, function and dysregulation in vascular disease. , 2012, Biochemical pharmacology.

[19]  J. Lindström,et al.  ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. , 2003, Clinical science.

[20]  D. Webb,et al.  Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade Mediated Vasodilatation Is Attenuated by Inhibition of − Endothelin-A Receptor Antagonist , 1998 .

[21]  T. Fukami,et al.  Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. , 1992, Life sciences.

[22]  R. Talanow,et al.  Regulation of the endothelin system by shear stress in human endothelial cells , 2000, The Journal of physiology.

[23]  L. Edvinsson,et al.  Increased expression of vascular endothelin type B and angiotensin type 1 receptors in patients with ischemic heart disease , 2009, BMC cardiovascular disorders.

[24]  D. Webb,et al.  Endothelium-derived endothelin-1 , 2010, Pflügers Archiv - European Journal of Physiology.

[25]  F. Ruschitzka,et al.  Mental Stress Induces Prolonged Endothelial Dysfunction via Endothelin-A Receptors , 2002, Circulation.

[26]  A. Davenport,et al.  Endothelin‐2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer , 2013, British journal of pharmacology.

[27]  P. Walker,et al.  Vascular Remodeling in the Internal Mammary Artery Graft and Association With In Situ Endothelin-1 and Receptor Expression , 2006, Circulation.

[28]  K. Pyke,et al.  Flow-mediated dilation stimulated by sustained increases in shear stress: a useful tool for assessing endothelial function in humans? , 2017, American journal of physiology. Heart and circulatory physiology.

[29]  D. Webb,et al.  Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography , 2000, Heart.

[30]  J. Rouleau,et al.  Reduced pulmonary clearance of endothelin-1 contributes to the increase of circulating levels in heart failure secondary to myocardial infarction. , 1998, Circulation.

[31]  P. Ganz,et al.  Role of Endothelin-1 in the Active Constriction of Human Atherosclerotic Coronary Arteries , 2001, Circulation.

[32]  Sadao Kimura,et al.  A novel potent vasoconstrictor peptide produced by vascular endothelial cells , 1988, Nature.

[33]  V. Richard,et al.  Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. , 2015, Kidney international.

[34]  M. Omata,et al.  Effects of hypertension, diabetes mellitus, and hypercholesterolemia on endothelin type B receptor-mediated nitric oxide release from rat kidney. , 1999, Circulation.

[35]  M. Turina,et al.  Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. , 1996, Journal of cardiovascular pharmacology.